Live Terminal | Security Analysis of AKRO
TERMINAL beta
Version: 0.1
Timestamp: 1708731042.643263
Options
100220.KS
52.83%
1809.TW
51.88%
006220.KS
49.51%
0756.HK
49.35%
B7J.DE
48.43%
0T8B.F
-39.43%
009310.KS
-40.63%
SZGPF
-42.69%
GOLL4.SA
-52.40%
HGEN.L
-53.56%
AAPL $182.88 -0.81%
AMD $176.41 -3.00%
AMZN $174.58 0.00%
BRK-B $417.87 0.65%
GOOG $145.44 0.08%
IBM $185.76 0.84%
INTC $43.28 0.71%
JNJ $161.87 0.89%
JPM $184.12 0.57%
META $488.06 0.40%
MSFT $410.31 -0.33%
O $53.27 0.85%
TSLA $195.04 -1.20%
WMT $176.24 0.47%
QQQ $437.06 -0.2306%
TLT $93.88 1.3441%
VUAA.DE $88.65 0.3918%
VUSA.DE $89.31 0.4025%
FJPR.L $5.64 1.5565%
VWRP.L $97.83 0.1638%
VWRL.L $98.54 0.1626%
EMGU.L $3.60 -0.1111%
RDVY $52.46 0.4211%
FLOT $50.99 0.0098%
SCHZ $45.73 0.3952%
IBB $138.22 0.7655%
C020.DE $21.34 0.0000%
DFAX $24.72 0.0862%
MEUD.PA $226.19 0.4173%
LYP6.DE $226.20 0.4440%
IDWR.L $71.10 0.4521%
IQQW.DE $65.72 0.3972%
EXS1.DE $145.70 0.2477%
XESC.L $6865.00 0.1240%
DFAU $35.28 0.1783%
ACWV $104.09 0.3277%
VHYD.L $63.92 0.2746%
VGWD.DE $59.24 0.5602%
FXKZ.ME $303.00 0.0000%

Latest articles

No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.

Sentiment statistics ?
AKRO
μ null
null
null

Financial Histories

Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.

Overview
AKRO
Latest Performance
AKRO$27.19
$2.98 • 12.31%
AKRO
Price 27.19
Change Pct 12.31
Change Abs 2.98
Market Cap 1.5 billion
Eps -2.29
Pe Ratio -11.87
Outstanding Shares 55.7 million
Volume 478209
Avg Volume 1.1 million
Industry Biotechnology
Sector Name Health Care
Country Short Name US
Announcement Earnings 2024-03-15 12:30:00+00:00
All metrics in USD or %.
Dividends

There is no dividend data to display. Refer our Dividend calendar for other accurate data.

Risk Profiles

Please sign up and become a member to view all risk profiles.

Competitors/Peer Groups
AKRO
Same Country:
Same Decade:
Intraday: +0.27%
Focus

The 'Focus' Area is meant to be an One-Pager about all Important Insights, Risks and Opportunities to solely analyze a single corporate.

Company descriptions
AKRO

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc.